Growth hormone secretagogue peptides: Mechanism of action and clinical potential
In this narrative review, we assess the efficacy of these pharmacotherapies and discuss other treatment approaches for MASLD/MASH, with a focus on their metabolic benefits
Abnehmmedikamente ergnzen oder ersetzen dieses Hormon und untersttzen so den Gewichtsverlust
Active or Historically Restrictive Eating Disorders NEDA, ANAD, and multiple clinical researchers now consider active restrictive eating disorders including anorexia nervosa and ARFID populations for whom GLP-1 medications pose serious and underappreciated risk
Gadd45 in the response of hematopoietic cells to genotoxic stress
doi:10.7570/jomes20028 Sepandi M, Samadi M, Shirvani H, et al